COLUMBIA, SC – October 6, 2020 – In view of National Breast Cancer Awareness Month, the American Cancer Society Cancer Action Network (ACS CAN) hosted its annual Ann “Tunky” Riley Pink Tea event last week to celebrate breast cancer survivors and honor those who have lost their li
The New York State Department of Health released statistics today showing that cancer patients and survivors still struggle with tobacco addiction. ACS CAN Senior New York Government Relations Director Julie Hart is calling for an increase in tobacco taxes and to use that revenue to fund the Tobacco Control Program.
ORLANDO, FL — October 5, 2020 — The COVID-19 pandemic has made it increasingly difficult for cancer patients and survivors to receive the care they need and has led to delays in preventive screenings, diagnostic testing and treatment care.
Today, the No on 814 – Campaign for a Healthier Oklahoma announced its coalition that asks voters to say “no” to State Question 814 on Nov. 3 and protect the Tobacco Settlement Endowment Trust (TSET) from sweeping changes that would funnel tens of millions of dollars away from critical programs that have helped 2.4 million Oklahomans.
On September 30, the Park MGM reopened as a smoke-free establishment amid the COVID-19 pandemic, marking the first time a casino will be smoke-free on the Strip. The American Cancer Society Cancer Action Network (ACS CAN) applauds the casino’s decision to protect the health of workers and patrons.
RALEIGH, NC – September 30, 2020 –Beginning this Thursday, a new law to help improve North Carolina cancer patients’ access to the most effective cancer treatments will take effect.
ATLANTA, GA— September 30, 2020 — The COVID-19 pandemic has largely uprooted cancer research with cancelled and delayed clinical research trials.
The American Cancer Society Cancer Action Network (ACS CAN) released new policy recommendations today to increase uptake of biomarker testing and advance the use of precision medicine in cancer care. The recommendations follow the release of new data that shows access is not keeping up with innovation when it comes to biomarker testing.
